Serum L-arginine and dimethylarginine levels in migraine patients with brain white matter lesions
Serum L-arginine and dimethylarginine levels in migraine patients with brain white matter lesions
复制标题
DOI:
10.1177/0333102416651454
复制
发表时间:
2017-05-01
期刊:
影响因子:
4.9
通讯作者:
Pfund, Zoltan
中科院分区:
文献类型:
--
作者:
Erdelyi-Botor, Szilvia;Komaromy, Hedvig;Pfund, Zoltan
Background/Aim: Migraine is a risk factor for the formation of silent brain white matter lesions (WMLs) that are possibly ischemic in nature. Although dysfunction of the L-arginine/nitric oxide (NO) pathway has been associated with oxidative stress and endothelial dysfunction in migraine, its role in WML development has not been specifically investigated. Thus, this prospective study aimed to measure the serum concentrations of the NO substrate L-arginine, the NO synthase inhibitor asymmetric dimethylarginine (ADMA), and the L-arginine transport regulator symmetric dimethylarginine (SDMA) in migraine patients in a headache-free period.Methods: All participants underwent MR imaging to assess for the presence of WMLs on fluid-attenuated inversion recovery imaging. Altogether 109 migraine patients (43 with lesions, 66 without lesions) and 46 control individuals were studied. High-performance liquid chromatography was used to quantify L-arginine, ADMA and SDMA serum concentrations. Migraine characteristics were investigated, and participants were screened for risk factors that can lead to elevated serum ADMA levels independent of migraine.Results: Migraine patients and controls did not differ in regard to vascular risk factors. Migraineurs with WMLs had a longer disease duration (p